Month: October 2022

Mao, Jie; Du, Peng; Yang, Han-teng; Hu, Huan; Wang, Shi-Yao; Wu, Xia; Cheng, Zhi-Bin published the artcile< Prognostic value of carbohydrate antigen125 and carcino embryonic antigen expression in patients with colorectal carcinoma and its guiding significance for chemotherapy>, Application of C20H21CaN7O7, the main research area is carcino embryonic antigen expression chemotherapy.

The aim of this study is to evaluate the predictive value of carbohydrate antigen125 (CA125) and carcino embryonic antigen (CEA) expression and its guiding role of choosing chemotherapy regimen in post-operation patients with colorectal carcinoma.The clin. data of all patients, including laboratory data and pathol. data, were collected from the electronic medical records. Kaplan-Meier Log rank test, COX regression model and subgroup analyses were employed to assess the correlation between the expression of CA125 and CEA in patients with colorectal carcinoma and the survival, and the effect on chemotherapy efficacy.Kaplan-Meier showed that CA125 expression is neg. related to the progression-free survival (PFS) of the post-operative patients, Median PFS was 1140 days in the patients with high expression, and Median PFS was 1387 days in the patients with low expression (Χ=4.715, P = .030); CEA expression is also neg. associated with the PFS of the post-operative patients, Median PFS was 1197 days in the patients with high expression, and Median PFS was 1424 days in the patients with low expression (Χ=4.992, P = .025). Subgroup anal. also showed that the patients with normal CA125 and CEA had better prognosis, median PFS was 1505 days, and the patients with CA125 and (or) CEA high expression had poor prognosis and median PFS was 1162 days (Χ=13.346, P = .001), and found that there was no statistical difference in patients with oxaliplatin plus capecitabine (XELOX) and oxaliplatin, 5-fluorouracil and Calcium folinate (FOLFOX) chemotherapy in patients with CA125 and CEA low expression. However, in these patients with CA125 or (and) CEA high expression, the median PFS of patients treated with XELOX was 1082 days, and the median PFS of patients treated with FOLFOX chemotherapy was 1335 (Χ=4.547, P = .033).Expression of CA125 and CEA associated with the survival of patients, and have some guiding significance for chemotherapy in patients with colorectal cancer after operation; Compared with XELOX, FOLFOX chemotherapy is more effective for CA125 or (and) CEA high expression patients with colorectal carcinoma.

Medicine (Philadelphia, PA, United States) published new progress about Analysis. 1492-18-8 belongs to class alcohols-buliding-blocks, and the molecular formula is C20H21CaN7O7, Application of C20H21CaN7O7.

Referemce:
Alcohol – Wikipedia,
Alcohols – Chemistry LibreTexts

Hu, Wei; Li, Changzhu; Dai, Jinming; Cui, Haiying; Lin, Lin published the artcile< Antibacterial activity and mechanism of Litsea cubeba essential oil against methicillin-resistant Staphylococcus aureus (MRSA)>, HPLC of Formula: 78-70-6, the main research area is Litsea Staphylococcus essential oil antibacterial cell hexose monophosphate pathway.

Litsea cubeba essential oil (LC-EO), one of the natural essential oils, could gradually replace chem. synthesis food additive in food industry due to its good antimicrobial activity. However, the antibacterial mechanism of the LC-EO is uncertain. This study took methicillin-resistant staphylococcus aureus (MRSA) as the research object to exposit its antibacterial mechanism. Research findings indicated the destructive effect of LC-EO on MRSA cell membrane, leading to intracellular biol. macromols. leakage. Whats more, the Hexose Monophophate Pathway (HMP) and its key enzyme (glucose-6-phosphate dehydrogenase) activity of MRSA were also inhibited after LC-EO treatment. Finally, the UV absorption spectroscopy result revealed that the key component of LC-EO (citral) could react with DNA in the form of chimera.

Industrial Crops and Products published new progress about Antibacterial agents. 78-70-6 belongs to class alcohols-buliding-blocks, and the molecular formula is C10H18O, HPLC of Formula: 78-70-6.

Referemce:
Alcohol – Wikipedia,
Alcohols – Chemistry LibreTexts

Dong, Yue; Sui, Mingrui; Jiang, Yiying; Wu, Jianyu; Wang, Xin published the artcile< Dibutyl phthalate weakens the role of electroactive biofilm as an efficient wastewater handler and related mechanism>, Reference of 492-62-6, the main research area is dibutyl phthalate electroactive biofilm wastewater handler related mechanism; Bacterial activity; Dibutyl phthalate exposure; Electroactive biofilm; Electron exchange capacity; Pollutant degradation.

Plasticizer plays an imperceptible role in interfering with the structure and function of wastewater biofilms, but the inherent influence mechanism still remains unknown. Here, the responses in electrochem., structural, microbial properties of electroactive biofilm (EAB) to plasticizer (di-Bu phthalate, DBP) were comprehensively elucidated, especially for the property variation of extracellular polymeric substances (EPS). The biofilm-0 in DBP-absent environment contributed to 22.9% and 63.9% higher current, compared to those in 1 mg/L and 10 mg/L DBP environment (biofilm-1 and biofilm-10). Chronic exposure to high-concentration DBP significantly boosted the content and distribution width of polysaccharide in EPS, but the electron exchange capacity of EPS decreased 76.6% to 0.146μmol e-/mg EPS for biofilm-10. The bacteria were subjected to metabolic function loss, in terms of esterase activity and membrane integrity, by using flow cytometry. The DBP exposure also imposed selective pressure on enrich EPS-secretion-related bacteria, while the Geobacter species decreased from 71.2% (biofilm-0) to 55.8% (biofilm-10). Consequently, the DBP exposure suppressed the pollutant degradation rate, which provided new insights into the EAB role as a promising core for wastewater treatment in plasticizer-existing environments.

Science of the Total Environment published new progress about Acinetobacter. 492-62-6 belongs to class alcohols-buliding-blocks, and the molecular formula is C6H12O6, Reference of 492-62-6.

Referemce:
Alcohol – Wikipedia,
Alcohols – Chemistry LibreTexts

Jeyaraman, Maya M; Al-Yousif, Nameer S H; Singh Mann, Amrinder; Dolinsky, Vernon W; Rabbani, Rasheda; Zarychanski, Ryan; Abou-Setta, Ahmed M published the artcile< Resveratrol for adults with type 2 diabetes mellitus.>, HPLC of Formula: 501-36-0, the main research area is .

BACKGROUND: Type 2 diabetes mellitus (T2DM) is a chronic disorder that is characterised by insulin resistance and hyperglycaemia, which over time may give rise to vascular complications. Resveratrol is a plant-derived nutritional supplement shown to have anti-diabetic properties in many animal models. Less evidence is available on its safety and efficacy in the management of T2DM in humans. OBJECTIVES: To assess the efficacy and safety of resveratrol formulations for adults with type 2 diabetes mellitus. SEARCH METHODS: We searched the Cochrane Central Register of Controlled Trials, MEDLINE, PubMed, Embase, the Cumulative Index to Nursing and Allied Health Literature (CINAHL), and International Pharmaceutical Abstracts, as well as the International Clinical Trials Registry Platform (ICTRP) Search Portal and ClinicalTrials.gov. The date of the last search was December 2018 for all databases. No language restrictions were applied. SELECTION CRITERIA: All randomised controlled trials (RCTs) comparing effects of oral resveratrol (any dose or formulation, duration, or frequency of administration) with placebo, no treatment, other anti-diabetic medications, or diet or exercise, in adults with a diagnosis of T2DM. DATA COLLECTION AND ANALYSIS: Two review authors independently identified and included RCTs, assessed risk of bias, and extracted study-level data. Study authors were contacted for any missing information or for clarification of reported data. We assessed studies for certainty of the evidence using the GRADE instrument. MAIN RESULTS: We identified three RCTs with a total of 50 participants. Oral resveratrol not combined with other plant polyphenols was administered at 10 mg, 150 mg, or 1000 mg daily for a period ranging from four weeks to five weeks. The comparator intervention was placebo. Overall, all three included studies had low risk of bias. None of the three included studies reported long-term, patient-relevant outcomes such as all-cause mortality, diabetes-related complications, diabetes-related mortality, health-related quality of life, or socioeconomic effects. All three included studies reported that no adverse events were observed, indicating that no deaths occurred (very low-quality evidence for adverse events, all-cause mortality, and diabetes-related mortality). Resveratrol versus placebo showed neutral effects for glycosylated haemoglobin A1c (HbA1c) levels (mean difference (MD) 0.1%, 95% confidence interval (CI) -0.02 to 0.2; P = 0.09; 2 studies; 31 participants; very low-certainty evidence). Due to the short follow-up period, HbA1c results have to be interpreted cautiously. Similarly, resveratrol versus placebo showed neutral effects for fasting blood glucose levels (MD 2 mg/dL, 95% CI -2 to 7; P = 0.29; 2 studies; 31 participants), and resveratrol versus placebo showed neutral effects for insulin resistance (MD -0.35, 95% CI -0.99 to 0.28; P = 0.27; 2 studies; 36 participants). We found eight ongoing RCTs with approximately 800 participants and two studies awaiting assessment, which, when published, could contribute to the findings of this review. AUTHORS’ CONCLUSIONS: Currently, research is insufficient for review authors to evaluate the safety and efficacy of resveratrol supplementation for treatment of adults with T2DM. The limited available research does not provide sufficient evidence to support any effect, beneficial or adverse, of four to five weeks of 10 mg to 1000 mg of resveratrol in adults with T2DM. Adequately powered RCTs reporting patient-relevant outcomes with long-term follow-up periods are needed to further evaluate the efficacy and safety of resveratrol supplementation in the treatment of T2DM.

The Cochrane database of systematic reviews published new progress about 501-36-0. 501-36-0 belongs to class alcohols-buliding-blocks, and the molecular formula is C14H12O3, HPLC of Formula: 501-36-0.

Referemce:
Alcohol – Wikipedia,
Alcohols – Chemistry LibreTexts

Khorana, Alok A.; McKernin, Shannon E.; Berlin, Jordan; Hong, Theodore S.; Maitra, Anirban; Moravek, Cassadie; Mumber, Matthew; Schulick, Richard; Zeh, Herbert J.; Katz, Matthew H. G. published the artcile< Potentially curable pancreatic adenocarcinoma: ASCO clinical practice guideline update>, Product Details of C20H21CaN7O7, the main research area is pancreatic adenocarcinoma adjuvant chemotherapy.

The purpose of this guideline update is to incorporate recently reported practice-changing evidence into ASCO’s recommendations on potentially curable pancreatic adenocarcinoma. ASCO convened an Expert Panel to evaluate data from PRODIGE 24/CCTG PA.6, a phase III, multicenter, randomized clin. trial of postoperative leucovorin calcium, fluorouracil, irinotecan hydrochloride, and oxaliplatin (FOLFIRINOX) vs. gemcitabine alone, presented at the 2018 ASCO Annual Meeting. In addition, PubMed was searched for addnl. papers that may influence the existing recommendations. The Expert Panel only updated Recommendation 4.1 as a result of the practice-changing data. Recommendation 4.1 states that all patients with resected pancreatic adenocarcinoma who did not receive preoperative therapy should be offered 6 mo of adjuvant chemotherapy in the absence of medical or surgical contraindications. The modified combination regimen of 5-fluorouracil, oxaliplatin, and irinotecan (mFOLFIRINOX; oxaliplatin 85 mg/m2, leucovorin 400 mg/m2, irinotecan 150 mg/m2 D1, and 5-fluorouracil 2.4 g/m2 over 46 h every 14 days for 12 cycles) is now preferred in the absence of concerns for toxicity or tolerance; alternatively, doublet therapy with gemcitabine and capecitabine or monotherapy with gemcitabine alone or fluorouracil plus folinic acid alone can be offered.

Journal of Clinical Oncology published new progress about Chemotherapy. 1492-18-8 belongs to class alcohols-buliding-blocks, and the molecular formula is C20H21CaN7O7, Product Details of C20H21CaN7O7.

Referemce:
Alcohol – Wikipedia,
Alcohols – Chemistry LibreTexts

Tamoradi, Taiebeh; Ghorbani-Choghamarani, Arash; Ghadermazi, Mohammad published the artcile< CoFe2O4@glycine-M (M = Pr, Tb and Yb): Three green, novel, efficient and magnetically-recoverable nanocatalysts for synthesis of 5-substituted 1H-tetrazoles and oxidation of sulfides in green condition>, Synthetic Route of 699-12-7, the main research area is tetrazole oxidation sulfide Cobalt ferrite glycine nanocatalyst green condition.

Three novel and green nano-scale magnetic solid base catalysts (CoFe2O4@glycine-M (M = Pr, Tb and Yb)) have been synthesized and characterized by XRD, TGA, VSM, EDX, ICP-OES, SEM and FT-IR spectroscopy. These robust nanohybrid catalysts as efficient and reusable heterogeneous nanocatalyst systems were used for synthesis of 5-substituted 1H-tetrazoles and sulfoxides in green condition. The present methodol. has outstanding advantages such as simplicity of procedure, facile synthesis, high activity, easy isolation of the products and reusability for several consecutive runs without significant loss of their catalytic efficiency.

Solid State Sciences published new progress about Nanocatalysts. 699-12-7 belongs to class alcohols-buliding-blocks, and the molecular formula is C8H10OS, Synthetic Route of 699-12-7.

Referemce:
Alcohol – Wikipedia,
Alcohols – Chemistry LibreTexts

Zhuo, Ming-Hua; Wilbur, David J.; Kwan, Eugene E.; Bennett, Clay S. published the artcile< Matching Glycosyl Donor Reactivity to Sulfonate Leaving Group Ability Permits SN2 Glycosylations>, Formula: C12H20O6, the main research area is beta glycosylation sulfonyl leaving group.

Here we demonstrate that highly β-selective glycosylation reactions can be achieved when the electronics of a sulfonyl chloride activator and the reactivity of a glycosyl donor hemiacetal are matched. While these reactions are compatible with the acid- and base-sensitive protecting groups that are commonly used in oligosaccharide synthesis, these protecting groups are not relied upon to control selectivity. Instead, β-selectivity arises from the stereoinversion of an α-glycosyl arylsulfonate in an SN2-like mechanism. Our mechanistic proposal is supported by NMR studies, kinetic isotope effect (KIE) measurements, and DFT calculations

Journal of the American Chemical Society published new progress about Arenesulfonyl chlorides Role: RCT (Reactant), RGT (Reagent), RACT (Reactant or Reagent). 4064-06-6 belongs to class alcohols-buliding-blocks, and the molecular formula is C12H20O6, Formula: C12H20O6.

Referemce:
Alcohol – Wikipedia,
Alcohols – Chemistry LibreTexts

Yang, Yifei; Wang, Yonghai; Zuo, Aixia; Li, Chunmei; Wang, Wenyan; Jiang, Wanglin; Zhang, Xiaochen; Che, Xin; Zhang, Yang; Wu, Wentao; Cen, Xiaobo; Wang, Hongbo; Tian, Jingwei published the artcile< Synthesis, biological, and structural explorations of a series of μ-opioid receptor (MOR) agonists with high G protein signaling bias>, Synthetic Route of 627-27-0, the main research area is mu opioid receptor agonist G protein signaling pharmacokinetics antinociceptive; Analgesia; Biased agonism; Respiratory repression; μ-opioid receptor.

Biased agonism refers to the ability of compounds to drive preferred signaling pathways and avoid adverse signaling pathways in a ligand-dependent manner for some G-protein-coupled receptors. It is thought that the separation of therapeutic efficacy (e.g., analgesia) from adverse effects (e.g., respiration depression) can be achieved through the design of biased MOR agonists and one example is the recently approved MOR biased agonist oliceridine (TRV130). However, oliceridine only demonstrates modest beneficial effects as compared to other opioids in terms of therapeutic/adverse effect balance. One possibility attributable to the modest success of oliceridine is its limited bias, and as such developing MOR ligands with a more biased agonism profile could in theory further improve the beneficial effects of the ligands. Here, we rationally designed and synthesized a series of derivatives as potent highly biased MOR agonists (19a-v) through the modification and structure-activity relationship study of TRV130. This novel synthetic mol., LPM3480392 (19m), demonstrated improved in vitro biased agonism (EC50 = 0.35 nM, Emax = 91.4%) with no measured β-arrestin recruitment (EC50 > 30000 nM, Emax = 1.6%), good brain penetration (B/P ratio = 4.61, 0.25 h post-IV dosing 2.0 mg/kg), a favorable pharmacokinetic profile (distribution volume = 10766 mL/kg, t1/2 = 1.9 h) and produced potent antinociceptive effect with reduced respiratory suppression (sO2(%) = 92.17, 0.32 mg/kg, SC) as compared to TRV130. LPM3480392 has completed preclin. studies and is currently under clin. development (CTR20210370) as an analgesic for the treatment of moderate to severe pain.

European Journal of Medicinal Chemistry published new progress about Affinity (binding). 627-27-0 belongs to class alcohols-buliding-blocks, and the molecular formula is C4H8O, Synthetic Route of 627-27-0.

Referemce:
Alcohol – Wikipedia,
Alcohols – Chemistry LibreTexts

Ochiai, Asako; Kuroda, Keiji published the artcile< Preconception resveratrol intake against infertility: Friend or foe>, Safety of (E)-5-(4-Hydroxystyryl)benzene-1,3-diol, the main research area is review endometriosis infertility resveratrol; aging; assisted reproductive technology; infertility; resveratrol; sirtuin.

A review. Growing evidence indicates that resveratrol has potential therapeutic effects in infertile women with diminished ovarian function, polycystic ovary syndrome (PCOS), or endometriosis. However, only one clin. trial in women undergoing in vitro fertilization (IVF) cycles using resveratrol has ever been reported. This review focuses on the potential therapeutic effects of resveratrol on pregnancy and on its advantages and disadvantages in pregnancy outcomes during infertility treatment. Methods : We performed a literature review to describe the known impacts of resveratrol on the ovary and endometrium. Results : Resveratrol upregulates sirtuin (SIRT)1 expression in ovaries, which is associated with protection against oxidative stress. It leads to the activation of telomerase activity and mitochondrial function, improving ovarian function. In the endometrium, resveratrol downregulates the CRABP2-RAR pathway leading to suppressing decidual and senescent changes of endometrial cells, which is essential for embryo implantation and placentation. Moreover, resveratrol may also induce deacetylation of important decidual-related genes. Conclusions : Resveratrol has potential therapeutic effects for improving ovarian function; however, it also has anti-deciduogenic actions in uterine endometrium. In addition, its teratogenicity has not yet been ruled out; thus, resveratrol should be avoided during the luteal phase and pregnancy.

Reproductive Medicine and Biology published new progress about Embryo, animal, two-cell. 501-36-0 belongs to class alcohols-buliding-blocks, and the molecular formula is C14H12O3, Safety of (E)-5-(4-Hydroxystyryl)benzene-1,3-diol.

Referemce:
Alcohol – Wikipedia,
Alcohols – Chemistry LibreTexts

Sivakumar, Ganesan; Subaramanian, Murugan; Balaraman, Ekambaram published the artcile< Single-Molecular Mn(I)-Complex-Catalyzed Tandem DoubleDehydrogenative Cross-Coupling of (Amino)Alcohols under Solventless Conditions with the Liberation of H2 and H2O>, Recommanded Product: (2-Aminophenyl)methanol, the main research area is quinoline pyridine preparation green; primary amino alc double dehydrogenative cross coupling manganese.

Sustainable chem. production requires fundamentally new types of catalysts and catalytic technologies. The development of coherent and robust catalytic systems based on earth-abundant transition metals is essential but extremely challenging. Herein, authors report the first report on a single Mn(I)-PNP catalyzed tandem C-C and C-N bond formation via double dehydrogenative coupling of amino alcs. with primary alcs. The current method covers a wide range of substrates, including aryl, aliphatic acyclic, and cyclic primary alcs., as well as amino alcs., to provide diverse N-heterocyclic compounds (pyridine and quinoline derivatives) in good to excellent yields (50 examples). The reaction proceeds under benign, solventless conditions with the liberation of mol. hydrogen and water as the only byproducts. Various control and labeling experiments and kinetic, NMR, and mechanistic studies suggest that the reaction operates via the acceptorless double dehydrogenative coupling pathway, selectively assimilating to provide desired N-heterocycles. Several selective bond activation/formation reactions occur sequentially via amine-amide metal-ligand cooperation.

ACS Sustainable Chemistry & Engineering published new progress about Amino alcohols Role: RCT (Reactant), RACT (Reactant or Reagent). 5344-90-1 belongs to class alcohols-buliding-blocks, and the molecular formula is C7H9NO, Recommanded Product: (2-Aminophenyl)methanol.

Referemce:
Alcohol – Wikipedia,
Alcohols – Chemistry LibreTexts